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Noriko Murase2, Yifan Dai2,8, Wanyu Wang9, Yuliang Xiong9, 
David J White4 and Robert Zhongl ,3,4,6,7,10 
We transplanted kidneys from 1X1,3-galactosyltransferase 
knockout (GaIT-KO) pigs into six baboons using two different 
immunosuppressive regimens, but most of the baboons died 
from severe acute humoral xenograft rejection. Circulating 
induced antibodies to non-Gal antigens were markedly elevated 
at rejection, which mediated strong complement-dependent 
cytotoxicity against GaIT-KO porcine target cells. These data 
suggest that antibodies to non-Gal antigens will present an 
additional barrier to transplantation of organs from GaIT-KO 
pigs to humans. 
Preformed antibodies directed against a specific oligosaccharide 
(Galrx 1-3Gal B 1-4GlcNAc; Gal) on the vascular endotheli urn of porcine 
blood vessels l -4 have precluded successful pig-to-higher-order primate 
xenotransplantation. Extensive pig-to-nonhuman primate experi-
ments have shown that Gal-specific antibodies not only cause hyper-
acute rejection (which occurs in a few hours), but also initiate acute 
humoral xenograft rejection (AHXR; which occurs in a few days to a 
few weeks)5-R. The recent production of cloned pigs lacking the 
galactosyltransferase enzyme (GalT-KO)9,lO raised hope that the 
organs from these animals would not only be spared from hyperacute 
rejection, but also would not be subject to AHXR. Here, we report our 
initial results of testing GalT-KO porcine kidneys in a life-supporting 
transplant model in baboons. The baboon recipients were immuno-
suppressed with either a multiagent immunosuppressive protocol, 
previously used to test transgenic porcine organs that express 
human decay accelerating factor (hDAF)11, or alternatively with 
a simpler 'tolerance-friendly' (a protocol with minimal immuno-
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suppression) treatment strategy of immunosuppression that has been 
used clinicallyl2. 
We performed six kidney transplants in baboons using GaIT-KO 
pigs as donors. We treated three of the baboons with a multiagent 
regimen that included a short course of thymoglobulin (ATG) 
followed by daily doses of tacrolimus, mycophenolate mofetil and 
steroids. We induced immunosuppression in the other three with a 
single high dose of ATG followed by monotherapy with tacrolimus 
('light therapy'; Table la and Supplementary Methods online). 
Both endothelial cells and lymphocytes, isolated from the GalT-KO 
donor pigs, had undetectable Gal expression measured by FACS when 
compared with the negative controls (Supplementary Fig. 1 online), 
confirming that the GalT-KO donor pigs were truly Gal-negative. 
All recipient baboons had low levels of preformed non -Gal-specific 
IgG and IgM (Table lb) before transplantation. Furthermore, sera 
collected from the recipient baboons before transplantation showed 
similar levels of complement-dependent cytotoxicity (CDC) against 
GalT-KO porcine lymphocytes as controls (Fig. la). None of the GaIT-
KO porcine grafts in this study developed hyperacute rejection. 
Table lb summarizes the clinical events and terminal graft histology 
for each animal. Using either immunosuppressive protocol, survival 
was limited between 8 and 16 d. Four baboons developed renal failure 
resulting from severe AHXR (Fig. lb), despite the fact that peripheral 
lymphocyte counts were well controlled at a level ofless than 0.5 x 109 
cellsll (Supplementary Fig. 2 online). AHXR was coincident with 
acute thrombocytopenia and proteinuria followed by marked eleva-
tions in serum creatinine, reduction of urine output and increase of 
non-Gal-specific antibody (Fig. Ie and Supplementary Fig. 2 online). 
Terminal pathology analysis from these four animals showed classic 
features of severe AHXR, characterized by massive interstitial hemor-
rhage, infarction, necrosis, thrombosis and loss of tubules with 
polymorph infiltration and massive deposition of IgG, IgM, C3, 
C4d (despite complement depletion with cobra venom factor) and 
platelets (Fig. ld). There was no notable change in the ELISA-
measured levels of either Gal-specific IgG or IgM in the sera of 
recipient baboons during the entire follow-up transplant period 
(Supplementary Fig. 3 online). The other two baboons (67-03 and 
65-03) died from Gram-negative bacterial sepsis or gastrointestinal 
bleeding on postoperative day 10 and 9, respectively. The pathology of 
renal grafts in these two cases showed only mild rejection (Grade I 
AHXR andlor AHXR; Table lb). 
Despite low levels of preformed antibodies to non-Gal antigens 
before transplantation, the porcine-specific antibodies were markedly 
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induced after grafting. In three of the four baboons that developed 
severe AHXR, circulating non-Gal IgG antibodies against donor 
lymphocytes increased 7-26-fold from baseline to the time of rejection 
(Table lb and Fig. Ie). There was also a 1.5-2.5-fold increase of anti-
non-Gal IgM levels in these three animals (Table Ib and Fig. Ie). The 
fourth baboon (66-03) had only a moderate increase in non-Gal-
specific IgG levels at the endpoint, but there was a threefold increase in 
non-Gal-specific IgM levels (Table lb) . Finally, the sera collected at 
the time of AHXR in these four baboons showed strong CDC (57.5-
66.8%) against lymphocytes from GalT-KO pigs (Fig. la). Similar 
results also were obtained when vascular endothelial cells were targets 
(Fig. Ie). The xenografts of baboons 67-03 and 65-03, which died 
from infection (65-03) or gastrointestinal bleeding (67-03) when 
AHXR or ACXR was only Grade I, had minimal elevations in non-
Gal-specific IgG antibody levels and no increase in non-Gal-specific 
IgM levels (Table lb) . At the endpoint, the sera collected from these 
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Figure 1 Elicited antibodies to non-Gal antigens lead to AHXR of GaiT-KG kidney grafts. (a) CDC against GaiT-KG porcine lymphocytes measured from sera 
collected before transplantation and on the day of death (Endpoint). Sera from 20-02, 64-03, 19-02 and 66-03 showed a marked elevation in CDC titers at 
the endpoi nt, when the xenografts developed severe AHXR . Target cells incubated with medium alone , without baboon serum and rabbit complement, served 
as medium control (M) and cells incubated with rabbit complement alone served as complement control (C). (b) Changes in serum creatinine levels of each 
recipient after transplantation . (c) Sequential measurement of antibodies to non-Gal antigens in the circulation and CDC to porcine GaiT-KG endothelial cells 
in a representative recipient (64-03) ; IgG levels (upper panels) and IgM levels (middle panels). Both IgG and IgM levels were measured by FACS using GaIT-
KG porci ne lymphocytes as targets. Cells were incubated with media and then stained with the secondary antibody serving as a control (dashed lines). Values 
represent geometric mean fluorescence intensity. There was marked elevation of both IgG and IgM antibodies to non-Gal antigens after GaiT-KG kidney 
grafting. Lower panels show CDC against porcine GaiT-KG endothelial cells. CDC increased after transplantation , and reached a peak level at the endpoint. 
(d ) Representative gross and pathological changes of a GaIT-KO kidney graft with severe AHXR in baboon 20-02 ; gross finding of the terminal graft (Gross); 
H&E staining of the terminal graft showing severe AHXR (HE) ; MSB staining of the terminal graft showing intravascular thrombosis (red stain with arrows, 
MSB). Immunopathology staining of the terminal graft showed positi ve platelet deposition (arrow, Platelet), massive IgM depOSition (arrow, IgM), massive IgG 
deposition (arrow, IgG), massive C3 deposition (arrow, C3) and positive C4d deposition (arrow, C4d) . (e) Representative photo of reactivit y of baboon serum 
(19-02) against GaIT-KO pig endothelial cells in western blots. Lane 1, incubated with baboon serum before transplantation (pre-Tx) and stained for human 
IgG, IgM and IgA antibodies; Lane 2, incubated with baboon serum at the endpoint stained with human IgG, IgM and IgA antibodies (left panel) . Intensity 
comparison between pre-transplantation and endpoint as determined by western blot (right panel). We performed signal quantification with ImageJ software 
(US National Institutes of Health). 
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Table la Immunosuppressive protocols 
Immunosuppressive protocols 
Immunosuppressants Multiagent Light 
Thymoglobulin (intravenous) 2.5 mglkg (day -2), 1.5-2.5 mglkg (days 0--7), 
targeting lymph count <0.5 x 109 
25 mglkg, once (day -1) 
Tacrolimus (per os) Dose 
Trough level 
4-5 mglkg twice daily (from day 0) 3-4 mglkg twice daily (from day 0) 
10--15 nglml 20-30 nglml 
Methylprednisolone (intravenous) 
MMF (per os) 
1.0 mglkg (days 0-2), tapered by 0.05 mglkgld to 0.2 mglkg 
25-30 mglkg twice daily (from day 8) 
1.0 g, once (day -1) 
None 
Cobra venom factor (intravenous) 0.05 mglkg (day -2), 0.02 mglkg every 36 h (days 1-14) None 
Table Ib Immunosuppressive protocol, antibody levels, survival, cause of death and terminal graft histology for individual animals 
Induced antibodies to 
Preformed antibodies to non-Gal antigens' non-Gal antigens' 
AnimallD Protocol IgG IgM IgG IgM Survival (d) Cause of death Graft histology 
20-02 Light 2.9 1.1 19.5 1.6 8 Renal fai lure AHXR III 
64-03 Light 3.4 1.0 88.1 2.5 11 Renal fai lure AHXR III 
67-03 Lightb 2.9 1.1 8.6 1.1 10 Sepsis AHXR I 
19-02 Multlagent 5.1 1.0 30 1.5 16 Renal failure AHXR III 
66-03 Multiagent' 2.7 1.1 7.2 3.0 13 Renal fai lure AHXR III 
65-03 Multiagentd 3.4 1.3 6.8 1.2 9 Gastrointestinal bleeding ACXR I, AHXR I 
'Antibody data presented are the ratio of relative mean fluorescence (RMF); underline indicates high values of induced antibodies to non-Gal antigens. bThis reCipient received 50 mglkg ATG for 
induction therapy. cThis recipient received 21 d of desensitization pretreatment (plasmapheresis and intravenous immunoglobulin five times, two doses of Rituxan and daily tacrolimus and MMF). 
dThlS recipient received cyclophosphamide Instead of ATG as induction therapy with splenectomy and Rituxan. MMF. mycophenolate mofetil; ACXR, acute cellular xenograft rejection. 
two baboons showed low titers of CDC «30%) against GaIT-KO 
porcine lymphocytes (Fig. Ia). The magnitude of the response of 
induced antibodies to non-Gal antigens, including CDC to GaIT-KO 
lymphocytes or endothelial cells, was well associated with severity of 
rejection, suggesting that induced antibodies against non-Gal epitopes 
were responsible for AHXR. 
To determine whether there were specific molecules that induced 
production of antibodies to non-Gal proteins during rejection, we 
performed western blotting using baboon sera against GaiT-KO pig 
endothelial cells (Supplementary Methods online). Incubation of 
baboon preoperative sera with the porcine endothelial cell lysate 
showed multiple bands (Fig. Ie). When incubated with sera collected 
at the endpoint of rejection, one of these bands at molecular weight of 
47 kDa was enhanced in all baboons except 66-03, in which the results 
were obscured by intravenous immunoglobulin the baboon received 
(Fig. Ie). These results indicate that a protein of 47 kDa isolated 
from porcine endothelial cells may be a major protein antigen that 
induced non-Gal antibody production during rejection. 
Our results were notably different from those reported by othersl3,14 
who transplanted kidneys and hearts from GaiT-KO miniature pigs, In 
those studies, elevated levels of antibodies against non-Gal antigens 
were not reported. Different immunosuppressive protocols, thymic 
radiation, co transplantation of donor thymus, two kinds of GaiT-KO 
pigs or different sources of the baboons may have contributed to the 
difference in the outcome. The inclusion of a CD154-specific mono-
clonal antibody in the immunosuppressive protocol used in these 
studies might effectively inhibit elicited antibodies I3,14. The clinical 
use of this antibody, however, has been hampered by its thrombotic 
tendencies lS• Furthermore, a high complication rate and mortality in 
their kidney transplant recipients were noted in their report13. We 
previously used the same multiagent immunosuppressive protocol 
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used in this study combined with the neutralization of Gal-specific 
antibodies in an hDAF pig-to-baboon kidney transplant modelil . A 
median 13-d survival (range, 7-75 d) was achieved in this study. These 
data suggest that, in the presence of an induced antibody response, 
genetic depletion of Gal antigens does not provide a major benefit in 
xenograft survival. 
In conclusion, kidneys from GaiT-KO pig donors are not hyper-
acutely rejected by baboons under different immunosuppressive regi-
mens. The problem posed by AHXR, however, has eluded solution. In 
our studies, AHXR was caused by induced antibodies to non-Gal 
antigens, and it seems essential to prevent this. Results from current 
studies in nonhuman primates are not promising enough to justify 
clinical trials. The future of xenotransplantation should emphasize 
further modification of donors, such as the combination of hDAF, 
GalT-KO, deletion of non-Gal antigens and adding a gene to inhibit 
coagulation dysregulation, rather than using more potent immuno-
suppressive agents in recipients. 
Note: Supplementary information is available on the Nature Medicine website. 
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